<DOC>
	<DOC>NCT01167426</DOC>
	<brief_summary>This is an open-label, multicenter study conducted at approximately 20 sites. Each patient will inject GA daily for 6 weeks utilizing an autoject 2 device to determine overall injection satisfaction.</brief_summary>
	<brief_title>Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) Patients</brief_title>
	<detailed_description>The study will consist of a 2 week treatment period with participants injecting their current therapy of Copaxone 20 mg/1.0 mL glatiramer acetate utilizing an autoject 2. All participants will then roll over to the new formulation of 20 mg/0.5 mL glatiramer acetate with an autoject 2 device for a 4 week treatment period. Patient satisfaction will be evaluated using an Experience Questionnaire throughout the study.</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Patients â‰¥ 18 years of age with a diagnosis of Relapse Remitting Multiple Sclerosis (RRMS) or Clinically Isolated Syndrome (CIS) Currently injecting glatiramer acetate 20 mg/1.0 mL per day subcutaneously (SC) for a minimum of 90 days utilizing the autoject 2 for glass syringe for a minimum of 75% of daily injections Willing and able to complete all procedures and evaluations related to the study Willing to continue to follow usual injection site preparation and routine adjunctive local injection site reactions (LISR) management techniques Willing and able to provide written informed consent Currently using or treated with another immunomodulating therapy (IMT) in conjunction with GA in the 30 days prior to screening for this study Currently using an investigational drug or using treatment with any other investigational agent in the 30 days prior to screening for this study Pregnant or planning pregnancy or breastfeeding Use of any other parenteral medications (e.g., intramuscular, SC, intravenous, etc.) either currently or in the past 30 days prior to screening for this study Any other medical or psychiatric conditions that would make the patient unsuitable for this research, as determined by the Investigator Unwilling to perform all daily injections with an autoject 2 device Previous participation in any study evaluating the new 20 mg/0.5 mL formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Relapsing Remitting Multiple Sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>Clinically Isolated Syndrome</keyword>
	<keyword>CIS</keyword>
	<keyword>Copaxone</keyword>
	<keyword>glatiramer acetate</keyword>
	<keyword>Autoject 2</keyword>
</DOC>